LA PrEP
Long-Acting Cabotegravir for HIV Prevention

Released: September 09, 2022

Expiration: September 08, 2023

Yvonne Gilleece
Yvonne Gilleece, MB, BCh, BAO, FRCP
Cristina Mussini
Cristina Mussini, MD
Babafemi Taiwo
Babafemi Taiwo, MBBS
Darrell H S Tan
Darrell H S Tan, MD, FRCPC, PhD

Activity

Progress
1
Course Completed

In this episode, an international expert panel shares their thoughts on key considerations for incorporating long-acting cabotegravir as an additional HIV pre-exposure prophylaxis option for appropriate individuals at high risk of acquiring HIV infection.

Topics include anticipated patient interest in this new paradigm, the role of the oral lead-in phase, new guideline recommendations for monitoring during PrEP, patient care and follow-up after PrEP discontinuation, and remaining unanswered questions.

Other episodes in this 4-part series cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, such as selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience; key considerations at the operational level for incorporating long-acting injectable ART into the HIV treatment armamentarium; and what is still needed in long-acting HIV care to further address patient needs and inequities across subgroups.